Compare Akamai Technologies, Inc. (AKAM) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Akamai Technologies, Inc. vs Novartis AG — how do they compare? Akamai Technologies, Inc. trades at $123.7 (market cap $16.77B), while Novartis AG trades at $152.63 (market cap $295.37B). The key difference: Novartis AG is far larger — about 17.6× Akamai Technologies, Inc.'s market cap, and Novartis AG pays a 3.07% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.
| AKAM | NVS | |
|---|---|---|
Market Cap | $16.77B | $295.37B |
Sector | Technology | Health |
52-Week High | $161.14 | $168.62 |
52-Week Low | $71.97 | $119.31 |
Enterprise Value | $22.75B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $117.65, up 6.43% on the day, buoyed by a recent analyst upgrade. The stock shows bearish technical signals but has beaten earnings estimates for three consecutive quarters, with Q2 2026 revenue growth of 5% year-over-year. Profit margins are under pressure due to increased infrastructure investments, though cloud and security demand remains strong.
The outlook is mixed: solid revenue growth and a consensus price target of $150.11 suggest upside, but margin compression and bearish technicals pose risks. Investors should weigh the company's strategic positioning in AI and cybersecurity against profitability challenges and market volatility.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
